New Delhi: Ahmedabad-based Cadila Pharmaceuticals is looking for global tie-ups to market its new patented product - Polycap - a combination of five medicines that prevents heart attack.
“We have already got regulatory approval to launch Polycap in India and for launching it in overseas market. Cadila is looking for tie-ups with global drug firms,” company’s Vice President-Medical Services Arun Masi said.
The company has the capability of launching the drug in Indian market, but in markets such as the US and Europe, it requires partnership with other firms, he said adding, “Partnership with global players is also required for getting regulatory approval and market access in developed countries.”
Cadila has already initiated talks with some multinational firms, he said while declining to divulge the names citing confidentiality as the reason.
The company has also applied for the nod of US health regulator Food and Drug Administration, but the issues such as patent rights of Polycap in overseas is yet to be decided, he added.
Polycap is a combination of three common anti-hypertensive drug, along with aspirin and a statin, a cholesterol lowering drug.
Cadila Pharmaceuticals will launch the drug in India by Cadila had recently submitted a study report on the five-in-one ‘Polycap´, at The American College of Cardiology, Orlando and was published online by the British medical journal, Lancet.